Veru (VERU) Current Deferred Revenue (2017 - 2018)
Veru (VERU) posted quarterly Current Deferred Revenue of $49095.0 for Q4 2018, down 95.04% year-over-year from $990016.0 in Q4 2017, and down 73.77% quarter-over-quarter from $187159.0 in Q3 2018.
Veru (VERU) Current Deferred Revenue (2017 - 2018) Analysis & Trends
Veru (VERU) has reported Current Deferred Revenue for 2 consecutive years, with $49095.0 the latest figure, recorded in Q4 2018.
- In Q4 2018, Current Deferred Revenue fell 95.04% year-over-year to $49095.0; the TTM figure through Dec 2018 stood at $49095.0 (down 95.04% YoY), while the FY2018 annual figure was $49095.0, changed N/A from the prior year.
- Current Deferred Revenue declined to $49095.0 in Q4 2018 per VERU's latest filing, from $187159.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $1.0 million in Q3 2017 and bottomed at $49095.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 49,095.00 |
| Sep 30, 2018 | 187,159.00 |
| Jun 30, 2018 | 760,981.00 |
| Mar 31, 2018 | 872,370.00 |
| Dec 31, 2017 | 990,016.00 |
| Sep 30, 2017 | 1.01 Mn |
| Jun 30, 2017 | 964,382.00 |